CA3239676A1 - Combination therapy comprising a pkc inhibitor and a c-met inhibitor - Google Patents

Combination therapy comprising a pkc inhibitor and a c-met inhibitor Download PDF

Info

Publication number
CA3239676A1
CA3239676A1 CA3239676A CA3239676A CA3239676A1 CA 3239676 A1 CA3239676 A1 CA 3239676A1 CA 3239676 A CA3239676 A CA 3239676A CA 3239676 A CA3239676 A CA 3239676A CA 3239676 A1 CA3239676 A1 CA 3239676A1
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3239676A
Other languages
English (en)
French (fr)
Inventor
Matthew Anthony MAUER
Michael Gabriel O'QUIGLEY
Richard Zang
Jaymes Holland
Mai Hope LE
Sarah Shwu-Kuan JAW-TSAI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Ideaya Biosciences Inc
Original Assignee
Pfizer Inc
Ideaya Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc, Ideaya Biosciences Inc filed Critical Pfizer Inc
Publication of CA3239676A1 publication Critical patent/CA3239676A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3239676A 2021-12-06 2022-12-05 Combination therapy comprising a pkc inhibitor and a c-met inhibitor Pending CA3239676A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163286345P 2021-12-06 2021-12-06
US63/286,345 2021-12-06
US202263317573P 2022-03-08 2022-03-08
US63/317,573 2022-03-08
US202263370056P 2022-08-01 2022-08-01
US63/370,056 2022-08-01
PCT/US2022/080928 WO2023107894A1 (en) 2021-12-06 2022-12-05 Combination therapy comprising a pkc inhibitor and a c-met inhibitor

Publications (1)

Publication Number Publication Date
CA3239676A1 true CA3239676A1 (en) 2023-06-15

Family

ID=86731264

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3239676A Pending CA3239676A1 (en) 2021-12-06 2022-12-05 Combination therapy comprising a pkc inhibitor and a c-met inhibitor

Country Status (8)

Country Link
US (1) US20240335440A1 (https=)
EP (1) EP4444303A4 (https=)
JP (1) JP2024542831A (https=)
AU (1) AU2022407330A1 (https=)
CA (1) CA3239676A1 (https=)
IL (1) IL313361A (https=)
MX (1) MX2024006948A (https=)
WO (1) WO2023107894A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014174478A1 (en) * 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
CA2955676A1 (en) * 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
US11413284B2 (en) * 2017-09-12 2022-08-16 Novartis Ag Protein kinase C inhibitors for treatment of uveal melanoma
AU2020386903A1 (en) * 2019-11-18 2022-06-09 Ideaya Biosciences, Inc. Dosing regimens for a protein kinase C inhibitor
JP2023541011A (ja) * 2020-09-08 2023-09-27 イデアヤ、バイオサイエンシズ、インコーポレイテッド 医薬組み合わせおよび腫瘍治療

Also Published As

Publication number Publication date
EP4444303A4 (en) 2025-11-26
EP4444303A1 (en) 2024-10-16
AU2022407330A1 (en) 2024-07-04
US20240335440A1 (en) 2024-10-10
WO2023107894A1 (en) 2023-06-15
JP2024542831A (ja) 2024-11-15
IL313361A (en) 2024-08-01
MX2024006948A (es) 2024-08-06

Similar Documents

Publication Publication Date Title
EP3574904B1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
US11260057B2 (en) Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer
US12427142B2 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl[oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid
US20240207257A1 (en) Combination therapy comprising a pkc inhibitor and a mek inhibitor
US20250090514A1 (en) Method of treating cancer
TW202332431A (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
AU2021382148A1 (en) Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
CN113194952A (zh) Hdm2-p53相互作用抑制剂和bcl2抑制剂的组合及其治疗癌症的用途
US12478614B2 (en) Inhibitors of glutathione s-transferases (GSTs) and NAD(P)H:quinone oxidoreductase 1 (NQO1), pharmaceutical compositions, and uses in managing cancer
EP3880207B1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
US20240335440A1 (en) Combination therapy comprising a pkc inhibitor and a c-met inhibitor
US11992478B2 (en) Methods of using androgen receptor inhibitors as cancer therapeutics
AU2024259627A1 (en) Methods of treating hepatic-only metastatic uveal melanoma
EP4085908A1 (en) Pharmaceutical combination for treating tumors and application thereof
CA3119395C (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
WO2024044775A1 (en) Methods of treating uveal melanoma
HK40018197A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
HK1204976B (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
BR112015002384B1 (pt) Combinações farmacêuticas compreendendo um inibidor de b-raf e um inibidor de egfr, e seus usos

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W019 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: OFFICE LETTER

Effective date: 20240702

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241015

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20241015

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241122

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241122

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241122

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241217

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250609

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20250609

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251125

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251125